Blue Ledge Capital

About The Fund

Blue Ledge Capital is a non-traditional venture capital firm that diverges from the standard VC model characterized by a 2 & 20 fee structure. Instead, they do not charge any recurring fees and aim to keep one-time syndication fees as low as possible, typically between 0-2%. The fundamental investment thesis of Blue Ledge Capital is to operate at breakeven until realization events allow the firm to share in the profits through a 20% performance fee, aligning the interests of the VC, its investors, and the companies they invest in. Blue Ledge focuses on quality over quantity and prides itself on transparency, offering investors extensive due diligence to review before they make investment decisions on an investment-by-investment basis, enabling investors to design their own portfolios based on their goals. Blue Ledge Capital specializes in Seed, Series A, and Series B stages, with a financial focus on FinTech and Financial Services. The firm's investment ranges from a minimum of $100,000 to a maximum of $5,000,000, with a sweet spot of approximately $1,500,000. The founder, Andy Roche, with his background in auditing and traditional finance, leverages his expertise to meticulously evaluate companies, particularly those who demonstrate technological advancement which align with the firm's mission to capitalize businesses committed to building the future. Blue Ledge has also partnered with institutional backers referred to as '5 Roses' that collectively manage a multibillion-dollar hedge fund, which supports Blue Ledge's sustainable model. The firm's investments include Respira Technologies, Mission Barns, Exogenesis, and Grolltex, each representing innovative solutions within their respective fields and aligning with Blue Ledge's theme of investing in the evolution and future of their industries.